DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• DAB2IP (Disabled-2 Interacting Protein) functions as a RAS GTPase-activating protein.
• DAB2IP loss or mutation is observed in tumor types lacking RAS mutations.
• Its role in RAS-mutant cancers, particularly colorectal cancer, remains less understood.

Purpose of the Study:

• To investigate the role of DAB2IP in colorectal cancers with KRAS and BRAF mutations.
• To elucidate the mechanisms by which DAB2IP loss impacts RAS signaling and tumor microenvironment.
• To identify potential therapeutic strategies targeting DAB2IP-deficient colorectal tumors.

Main Methods:

• Analysis of DAB2IP mutation and silencing in colorectal cancer datasets.
• In vivo studies to assess the impact of DAB2IP loss on RAS activation, inflammation, and macrophage recruitment.
• Pharmacological inhibition of inflammatory pathways (JAK/TBK1) and macrophage depletion.

Main Results:

• DAB2IP is frequently mutated or silenced in KRAS/BRAF mutant colorectal cancers.
• DAB2IP loss activates wild-type H- and N-RAS, enhancing RAS effector pathways in KRAS-mutant tumors.
• DAB2IP deficiency triggers inflammatory mediator production and protumorigenic macrophage infiltration.
• Inhibition of inflammation or macrophage depletion suppressed tumor growth in vivo.
• DAB2IP loss occurs early in tumor development and correlates with inflammatory signatures in human tumors.

Conclusions:

• DAB2IP loss is a common mechanism amplifying RAS signaling and inflammation in colorectal cancer.
• DAB2IP restrains RAS pathway activation and inflammatory cascades in the colon.
• Targeting inflammatory pathways or macrophages may be effective in treating DAB2IP-deficient colorectal cancers.